Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited)

v3.20.2
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Gain (loss) [Member]
Accumulated Deficit [Member]
Series B Convertible Preferred Stock [Member]
Total
Balance, at beginning at Dec. 31, 2018   $ 212,157 $ (41) $ (188,452)   $ 23,664
Balance, at beginning (in shares) at Dec. 31, 2018 328,689       9,856  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon conversion of Series B Convertible preferred stock $ 1 (1)        
Issuance of common stock upon conversion of Series B Convertible preferred stock (in shares) 281,610       (9,856)  
Issuance of common stock in exchange for exercise of warrants in March 2019 ($35.00 per share)   70       70
Issuance of common stock in exchange for exercise of warrants in March 2019 ($35.00 per share) (in shares) 2,000          
Employee stock purchase plan   3       3
Employee stock purchase plan (in shares) 177          
Stock-based compensation   305       305
Foreign currency translation gain     2     2
Net loss       (6,233)   (6,233)
Balance, at end at Mar. 31, 2019 $ 1 212,534 (39) (194,685)   17,811
Balance, at end (in shares) at Mar. 31, 2019 612,476          
Balance, at beginning at Dec. 31, 2018   212,157 (41) (188,452)   23,664
Balance, at beginning (in shares) at Dec. 31, 2018 328,689       9,856  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss           (12,073)
Balance, at end at Jun. 30, 2019 $ 1 213,385 (39) (200,525)   12,822
Balance, at end (in shares) at Jun. 30, 2019 637,335          
Balance, at beginning at Mar. 31, 2019 $ 1 212,534 (39) (194,685)   17,811
Balance, at beginning (in shares) at Mar. 31, 2019 612,476          
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock under 2018 Purchase Agreement   387       387
Issuance of common stock under 2018 Purchase Agreement (in share) 22,754          
Issuance of common stock under At-the-market offering, net of transactional expenses of $1   33   33
Issuance of common stock under At-the-market offering, net of transactional expenses of $1 (in share) 2,105          
Stock-based compensation   431       431
Net loss       (5,840)   (5,840)
Balance, at end at Jun. 30, 2019 $ 1 213,385 (39) (200,525)   12,822
Balance, at end (in shares) at Jun. 30, 2019 637,335          
Balance, at beginning at Dec. 31, 2019 $ 9 226,524 (46) (217,070)   9,417
Balance, at beginning (in shares) at Dec. 31, 2019 8,531,504          
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share) $ 13 7,461       7,474
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share) (in shares) 13,111,999          
Deemed dividend in connection with repricing of November 2019 warrants   451       451
Warrant deemed dividend   (451)       (451)
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711)     4,602     4,602
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711) (in shares)         5,313  
Beneficial conversion feature in connection with issuance of Series B Convertible preferred stock   1,260       1,260
Preferred stock deemed dividend   (1,260)       (1,260)
Issuance of common stock and common stock warrants in February 2020 ($0.57 per share, net of transactional expenses of $292) $ 4 1,891       1,895
ssuance of common stock and common stock warrants in February 2020 ($0.57 per share, net of transactional expenses of $292) (in shares) 3,837,000          
Issuance of common stock upon conversion of Series B Convertible preferred stock $ 9 (9)        
Issuance of common stock upon conversion of Series B Convertible preferred stock (in shares) 9,321,053       (5,313)  
Issuance of common stock in March 2020 ($1.10 per share, net of transactional expenses of $1,221) $ 14 14,770       14,784
Issuance of common stock in March 2020 ($1.10 per share, net of transactional expenses of $1,221) (in shares) 14,550,000          
Employee stock purchase plan   2       2
Employee stock purchase plan (in shares) 1,578          
Stock-based compensation   360       360
Foreign currency translation gain     (14)     (14)
Net loss       (7,273)   (7,273)
Balance, at end at Mar. 31, 2020 $ 49 255,601 (60) (224,343)   31,247
Balance, at end (in shares) at Mar. 31, 2020 49,353,134          
Balance, at beginning at Dec. 31, 2019 $ 9 226,524 (46) (217,070)   $ 9,417
Balance, at beginning (in shares) at Dec. 31, 2019 8,531,504          
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock under 2019 Purchase Agreement (in share)           464,471
Preferred stock deemed dividend           $ (1,260)
Net loss           (21,452)
Balance, at end at Jun. 30, 2020 $ 105 292,058 (69) (238,522)   53,572
Balance, at end (in shares) at Jun. 30, 2020 104,803,906          
Balance, at beginning at Mar. 31, 2020 $ 49 255,601 (60) (224,343)   31,247
Balance, at beginning (in shares) at Mar. 31, 2020 49,353,134          
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock under 2019 Purchase Agreement $ 1 277       278
Issuance of common stock under 2019 Purchase Agreement (in share) 464,471          
Issuance of common stock in May and June 2020 under At-the-market offering, net of transaction expenses of $1,131 $ 53 34,089       34,142
Issuance of common stock in May and June 2020 under At-the-market offering, net of transaction expenses of $1,131 (in share) 52,986,301          
Issuance of common stock in the acquisition of Trigemina assets $ 2 1,358       1,360
Issuance of common stock in the acquisition of Trigemina assets (in share) 2,000,000          
Stock-based compensation   733       733
Foreign currency translation gain     (9)     (9)
Net loss       (14,179)   (14,179)
Balance, at end at Jun. 30, 2020 $ 105 $ 292,058 $ (69) $ (238,522)   $ 53,572
Balance, at end (in shares) at Jun. 30, 2020 104,803,906